List of Excipients in Branded Drug MEKTOVI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Array BioPharma Inc	MEKTOVI	binimetinib	70255-010	CELLULOSE, MICROCRYSTALLINE	2033-10-18
Array BioPharma Inc	MEKTOVI	binimetinib	70255-010	CROSCARMELLOSE SODIUM	2033-10-18
Array BioPharma Inc	MEKTOVI	binimetinib	70255-010	FERRIC OXIDE YELLOW	2033-10-18
Array BioPharma Inc	MEKTOVI	binimetinib	70255-010	FERROSOFERRIC OXIDE	2033-10-18

Mektovi Excipient Strategy and Commercial Opportunities for Binimetinib

Last updated: August 22, 2026

Mektovi (binimetinib) is an orally administered, film-coated small-molecule tablet marketed by Pfizer after its acquisition of Array BioPharma. Its commercial formulation uses a conventional immediate-release tablet platform with lactose monohydrate, microcrystalline cellulose, magnesium stearate and colloidal silicon dioxide in the core, plus a polymeric film coating. The main excipient opportunities are generic-development support, supply security, low-dose content uniformity, coating optimization and differentiated oral solid-dose manufacturing.

Mektovi has no biosimilar pathway because binimetinib is a chemically synthesized small molecule. Market entry would proceed through an abbreviated new drug application, subject to Orange Book patent certifications, bioequivalence and any applicable regulatory exclusivity.

What is Mektovi and how is it formulated?

Mektovi contains binimetinib, a reversible inhibitor of MEK1 and MEK2. The U.S. Food and Drug Administration approved Mektovi in June 2018 in combination with encorafenib for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation (FDA, 2018).

Mektovi dosage forms and strengths

Attribute	Publicly reported information
Active ingredient	Binimetinib
Brand	Mektovi
Dosage form	Immediate-release, film-coated tablet
Strengths	15 mg and 45 mg
Standard adult dose	45 mg orally twice daily with encorafenib
Lower dose strength	15 mg, used for dose reductions
Administration	With or without food
Primary combination product	Braftovi, or encorafenib
FDA approval	June 27, 2018
Original developer	Array BioPharma
Current commercial owner	Pfizer

The prescribing information identifies the tablet core as containing lactose monohydrate, microcrystalline cellulose, magnesium stearate and colloidal silicon dioxide. The film coating contains standard coating materials, including a polymer, plasticizer, pigment and opacifying agents. Exact supplier grades are not generally disclosed in FDA labeling (FDA, 2024a).

What excipients are used in Mektovi tablets?

The Mektovi formulation uses a standard wet- or dry-granulated oral solid-dose architecture, although the precise manufacturing process is proprietary.

Core excipients

The disclosed core excipients have distinct functional roles:

Excipient	Functional role	Commercial relevance
Lactose monohydrate	Diluent and compressibility aid	Creates supplier qualification and lactose-allergen labeling considerations
Microcrystalline cellulose	Diluent, binder and disintegration-support excipient	Supports tablet robustness and low-dose uniformity
Magnesium stearate	Lubricant	Excessive use can slow dissolution
Colloidal silicon dioxide	Glidant and moisture-control aid	Supports powder flow and blend uniformity

The 15 mg strength creates a more demanding content-uniformity problem than the 45 mg strength because the active ingredient represents a smaller share of tablet mass. A generic manufacturer may use a formulation that differs quantitatively from Mektovi if it delivers equivalent performance and meets regulatory requirements.

Film-coating system

The film coating has several commercial functions:

• Protecting the tablet surface
• Improving swallowability
• Controlling appearance and product identification
• Supporting mechanical durability during packaging and distribution
• Reducing exposure to light or moisture where necessary

Coating suppliers can compete through ready-to-use premixes, lower-temperature processing, faster coating cycles, reduced spray-drying losses and improved color consistency. A yellow or otherwise distinctive coating also creates a practical product-identification requirement for generic manufacturers.

What formulation risks affect generic Mektovi development?

The principal development risks are not the number of excipients. They are low-dose blend uniformity, dissolution control, tablet mechanical properties and exposure to formulation changes.

Low-dose content uniformity

Binimetinib is present at 15 mg in the lower-strength tablet. Developers must control:

• API particle-size distribution
• API agglomeration
• Blend segregation
• Order of ingredient addition
• Lubrication time
• Sampling strategy
• Compression-force variability

Microcrystalline cellulose and colloidal silicon dioxide can improve flow and blend behavior, but both can also alter density and segregation risk when the API has materially different particle characteristics.

Dissolution and bioequivalence

Magnesium stearate concentration and mixing time can materially affect wetting and dissolution. A generic formulation that matches assay and content uniformity but has a slower dissolution profile may fail comparative performance requirements.

The key development variables include:

1. API particle size and polymorphic form.
2. Diluent ratio and grade.
3. Lubricant level and lubrication time.
4. Tablet hardness and porosity.
5. Film-coating weight gain.
6. Dissolution across pH conditions.

Because Mektovi is administered with or without food, food-effect performance is commercially important. A formulation that is unusually sensitive to gastric conditions could create regulatory and clinical-development problems.

Excipient compatibility

Potential compatibility work should focus on:

• Binimetinib interaction with reducing sugars in lactose
• Moisture uptake
• Oxidation and light exposure
• Magnesium stearate-related dissolution changes
• Coating-polymer permeability
• Long-term impurity formation
• Extractables and leachables from packaging

The presence of lactose does not automatically require a generic product to use lactose. A lactose-free formulation could be commercially attractive for selected markets, but it would require evidence that the substitution does not alter bioequivalence, stability or manufacturing performance.

What commercial opportunities exist in Mektovi excipients?

The most practical opportunities fall into four groups: supply, formulation development, manufacturing services and differentiated product design.

1. Excipient supply and dual sourcing

Mektovi uses high-volume compendial excipients rather than rare functional materials. This limits pricing power for commodity-grade lactose, cellulose and magnesium stearate. The stronger opportunity is qualified supply with:

• Tight particle-size specifications
• Low bioburden and controlled endotoxin levels
• Consistent bulk density
• Reliable global availability
• Regulatory documentation
• Change-control discipline
• Regional manufacturing redundancy

Suppliers with pharmaceutical-grade lactose and microcrystalline cellulose can target generic developers, contract development and manufacturing organizations, and regional finished-dose manufacturers.

2. Co-processed excipients

Co-processed filler-binder or flow-enhancing systems could reduce development time. Potential benefits include:

• Better low-dose blend uniformity
• Improved flow into the tablet press
• Lower compression-force requirements
• Reduced sensitivity to API particle-size variation
• Faster scale-up
• More consistent dissolution

A co-processed excipient is commercially relevant only if it produces a measurable manufacturing or performance benefit. Replacing one conventional diluent with another does not create a strong product position by itself.

3. Film-coating platforms

Ready-to-use coating systems offer a more defensible commercial opportunity than commodity tablet-core materials. Suppliers can differentiate through:

• Lower coating weight
• Shorter process time
• Improved adhesion
• Lower residual moisture
• Better resistance to abrasion
• Stable color matching
• Reduced solvent or energy use

A coating system that reproduces Mektovi’s visual appearance while improving process economics could support generic and contract-manufacturing programs.

4. CDMO formulation and analytical services

Mektovi is suitable for a focused oral-solid-dose CDMO offering covering:

• API characterization
• Excipient compatibility
• Formulation screening
• Blend-uniformity studies
• Tablet compression
• Film coating
• Dissolution method development
• Stability programs
• Comparative bioequivalence batches
• ANDA manufacturing support

The 15 mg and 45 mg strengths create an opportunity for platform formulations, but the lower strength must be separately demonstrated for uniformity and dissolution.

What patents protect Mektovi and its formulation?

Mektovi’s commercial protection is primarily tied to binimetinib, therapeutic use, solid-state and formulation claims, rather than to the commercial value of ordinary excipients.

Patent and regulatory protection

Protection category	Relevance to Mektovi
Active-ingredient patents	Can protect binimetinib composition or chemical matter
Solid-form patents	Can protect a particular crystalline or solid-state form
Formulation patents	May cover tablet composition, dosage form or release characteristics
Method-of-use patents	May cover treatment of BRAF-mutant melanoma or combination therapy
Orange Book listings	Identify patents submitted for the approved drug
New chemical entity exclusivity	Five years from FDA approval, subject to applicable exceptions
Pediatric exclusivity	Adds six months only if granted
ANDA pathway	Generic applicants must address listed patents and exclusivity

The FDA approved Mektovi on June 27, 2018. Five-year new chemical entity exclusivity therefore reached its ordinary endpoint in June 2023, assuming no separate regulatory extension. The FDA Orange Book, not the prescribing information, controls the current list of patents submitted for Mektovi and the associated expiration information (FDA, 2024b).

Are Mektovi excipients separately patented?

The disclosed excipients are established pharmaceutical materials. Their presence in Mektovi does not indicate that Pfizer has a broad proprietary right over lactose, microcrystalline cellulose, magnesium stearate or colloidal silicon dioxide.

A formulation patent could still create risk if it claims:

• A narrow quantitative excipient range
• A specific polymorph or particle-size distribution
• A defined dissolution profile
• A particular combination of binimetinib and excipients
• A manufacturing process
• A coating architecture
• A stability-enhancing formulation

A generic manufacturer can often design around such claims by changing excipient grades, ratios, process parameters or coating composition. The commercial value of any design-around depends on the claim language and the Orange Book patent status.

When does Mektovi lose exclusivity?

Mektovi’s five-year FDA new chemical entity exclusivity ended in 2023. That date did not automatically authorize generic launch because patent rights may continue after regulatory exclusivity expires.

Generic entry timeline

Event	Timing
FDA approval of Mektovi	June 27, 2018
Standard NCE exclusivity endpoint	June 27, 2023
Potential ANDA filing after NCE exclusivity	Generally available subject to other restrictions
Paragraph IV challenge	Possible against eligible listed patents
Generic launch	Depends on patent outcome, settlement, judgment or expiry
Biosimilar entry	Not applicable

The commercial entry date depends on the patents listed in the current Orange Book, any Paragraph IV litigation, court outcomes and settlement terms. A generic applicant may file a Paragraph IV certification asserting that a listed patent is invalid, unenforceable or not infringed. The filing can trigger litigation and a potential 30-month stay under the Hatch-Waxman framework if the patent holder sues within the statutory period (FDA, 2024b).

What is the Orange Book status of Mektovi?

Mektovi is an FDA-approved small-molecule drug listed in the Orange Book under its NDA. The Orange Book identifies approved products, therapeutic equivalence information and patents submitted by the NDA holder.

Orange Book and Paragraph IV considerations

A prospective generic applicant should evaluate:

• Whether active patents remain listed
• Whether patents claim the tablet, method of use or other approved aspects
• Whether a certification can be made under Paragraph I, II, III or IV
• Whether a section viii statement can carve out a patented indication
• Whether the proposed label can omit protected use information
• Whether patent litigation has resulted in a judgment or settlement
• Whether an authorized generic or license arrangement exists

Mektovi is used with encorafenib, so method-of-use analysis must distinguish binimetinib claims from combination-treatment claims covering both products.

Which companies are challenging Mektovi exclusivity?

No publicly verified Paragraph IV challenger, litigation outcome or Mektovi-specific settlement is established in the sources cited here. The competitive threat should therefore be assessed through the current Orange Book, FDA Paragraph IV notices where available, federal court dockets and ANDA litigation records.

Potential participants include:

• Large generic manufacturers
• Specialty oncology generic companies
• Regional manufacturers with oncology portfolios
• CDMOs developing products for license
• Companies pursuing authorized-generic transactions

The absence of a publicly identified challenger in the cited record does not eliminate future entry risk.

How strong is the Mektovi patent estate?

The estate is likely strongest where claims cover binimetinib chemical matter, specific solid forms, approved combination therapy or narrow therapeutic uses. It is weaker against a generic that can use a different solid form, excipient ratio, coating system or manufacturing process without infringing valid claims.

Patent-strength factors

Factor	Business impact
Remaining patent term	Determines time to potential generic launch
Claim breadth	Controls design-around difficulty
Patent validity history	Affects Paragraph IV settlement leverage
Solid-form coverage	Can constrain API sourcing
Method-of-use coverage	May permit label carve-outs or limit use
Formulation specificity	Determines excipient substitution options
Manufacturing claims	Can create API or process barriers
Patent-family overlap	Can extend practical litigation exposure

Excipient patents generally provide a secondary barrier. The stronger commercial barriers are API access, solid-state control, bioequivalence, oncology distribution and patent claims that reach the approved combination regimen.

What manufacturing and IP barriers affect Mektovi generic entry?

Generic developers face a manageable formulation challenge but a more significant legal and supply-chain assessment.

Manufacturing barriers

Key barriers include:

• Reproducing low-dose content uniformity
• Controlling API particle size and solid form
• Maintaining dissolution across strengths
• Achieving robust coating adhesion
• Demonstrating stability in commercial packaging
• Sourcing consistent pharmaceutical-grade excipients
• Establishing a validated analytical method
• Producing both 15 mg and 45 mg strengths economically

The 15 mg strength can increase cost because it may require separate blend controls, compression settings or manufacturing validation. A common platform formulation could lower cost, but it must demonstrate performance for each strength.

Geographic coverage

Patent protection is jurisdiction-specific. U.S. Orange Book listings do not determine European, Canadian, Japanese, Australian or emerging-market patent status. Generic developers must separately review:

• U.S. patents and Hatch-Waxman litigation
• European Patent Office family members
• National validations and supplementary protection certificates
• Local regulatory exclusivity
• Data-exclusivity periods
• Country-specific patent term adjustments
• Manufacturing and import restrictions

A product may face U.S. patent risk while being commercially available in a country with no blocking patent, or the reverse.

How does Mektovi compare with competing oral oncology products?

Mektovi differs from many targeted oncology products because its commercial use is closely linked to encorafenib.

Product	Active ingredient	Form	Commercial distinction
Mektovi	Binimetinib	Film-coated tablet	MEK inhibitor used with encorafenib
Braftovi	Encorafenib	Capsule	BRAF inhibitor paired with Mektovi
Mekinist	Trametinib	Tablet	Competing MEK inhibitor, commonly paired with dabrafenib
Cotellic	Cobimetinib	Tablet	MEK inhibitor, commonly paired with vemurafenib

For excipient suppliers, the Mektovi-Braftovi regimen creates a coordinated packaging and supply opportunity. A generic Mektovi product may have limited commercial value if a compatible generic encorafenib product is not available or if prescribers remain tied to the branded combination.

What revenue exposure and commercial opportunities exist?

Pfizer reports oncology performance at a portfolio level, and public company reporting may not provide a consistent standalone Mektovi revenue line for every period. The principal commercial exposure is therefore linked to:

• Continued use of the encorafenib-binimetinib combination
• Expansion or contraction of BRAF-mutant melanoma treatment
• Competition from other BRAF/MEK combinations
• Generic entry timing
• Pricing pressure after patent or regulatory barriers fall
• Reimbursement and specialty-pharmacy access

For excipient companies, the addressable opportunity is smaller than the finished-drug market. It is concentrated in repeat supply contracts, generic development projects, coating systems and CDMO work rather than in royalty participation from the branded product.

Key Takeaways

• Mektovi is a 15 mg and 45 mg immediate-release, film-coated binimetinib tablet.
• Its disclosed formulation uses lactose monohydrate, microcrystalline cellulose, magnesium stearate and colloidal silicon dioxide in the core.
• The strongest excipient opportunities are dual sourcing, co-processed excipients, film coatings and generic-development services.
• The 15 mg tablet creates the main technical risk because of low-dose content uniformity.
• Mektovi’s five-year NCE exclusivity ended in June 2023.
• Generic entry remains dependent on current Orange Book patents, Paragraph IV activity, litigation and settlement terms.
• Biosimilar competition does not apply because binimetinib is a small molecule.
• Excipient patents are likely to be less important than API, solid-form, method-of-use and manufacturing claims.
• Commercial demand is linked to the Mektovi-Braftovi combination and the broader BRAF/MEK inhibitor market.

FAQs About Mektovi Excipients and Generic Entry

Does Mektovi contain lactose?

Yes. U.S. prescribing information identifies lactose monohydrate as a Mektovi tablet-core excipient (FDA, 2024a).

Can a generic Mektovi tablet use different excipients?

Yes. A generic applicant generally may use a different quantitative or qualitative excipient composition if the product meets applicable quality, bioequivalence, stability and labeling requirements.

Is Mektovi a biologic that can face biosimilar competition?

No. Mektovi contains binimetinib, a chemically synthesized small molecule. Competition would generally occur through the ANDA generic-drug pathway rather than through a biosimilar application.

What is the main formulation challenge for generic binimetinib?

The main challenge is achieving consistent low-dose content uniformity and comparable dissolution for the 15 mg strength while maintaining stability and tablet robustness.

Are Mektovi’s excipients likely to block generic entry?

Ordinary excipients such as lactose, microcrystalline cellulose and magnesium stearate are unlikely by themselves to block entry. Blocking risk depends on enforceable patents covering binimetinib, a solid form, formulation parameters, manufacturing methods or approved methods of use.

References

1. U.S. Food and Drug Administration. (2018). FDA approves encorafenib with binimetinib for metastatic melanoma with a BRAF V600E or V600K mutation. https://www.fda.gov
2. U.S. Food and Drug Administration. (2024a). Mektovi (binimetinib) prescribing information. Pfizer Laboratories. https://labeling.pfizer.com
3. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
4. Pfizer Inc. (2024). Annual report. https://www.pfizer.com/investors/financial-reports
5. European Medicines Agency. (2018). Mektovi: EPAR product information. https://www.ema.europa.eu